67 / 1084
3/28/2017
9
ASGBI 2008
OEO2 update
Resection Details
CS
S
Number having
surgery
361
386
Median time to
surgery
63 days
16 days
Perioperative
deaths
36 (10%)
40 (10%)
R0
60%
55%
R1
18%
15%
R2
9%
13%
Inoperable
5%
14%
ASGBI 2008
OE02 update
# at risk
S
CS
S
CS
HR (95% CI) = 0.84 (0.72, 0.98)
p=0.03
–
Updated results
–
Overall survival (from randomisation)
Treatment and Surgery
897patients
CF (451)
1cycle
(14,3%)
Surgery
(11,2%)
2cycles
(435,96%)
Surgery
(400,89%)
Allpatients
(451)
Surgery
(411,91%)
ECX(446)
1cycle
(12,3%)
Surgery
(8,2%)
2cycles
(32,7%)
Surgery
(21,5%)
3cycles
(37,8%)
Surgery
(27,6%)
4cycles
(363,81%)
Surgery
(331,74%)
Allpatients
(446)
Surgery
(387,87%)
Of the 798 who had surgery, 47 (24 CF, 23 ECX) had an open and close operation.
Alderson,Cunninghamet al ASCO 2015
Surgery
CF
(N=451)
ECX
(N=446)
n % n % P-
value
Surgery performed
Yes
411
91%
387
87%
0.043
No
40
9%
59
13%
Reason for no
surgery
PD, inoperable, co-
morbidity
37
44
Patient choice
2
7
Died
1
8
Resection
Yes
387
94%
364
94%
1.000
No
24
6%
23
6%
Alderson,Cunninghamet al ASCO 2015
Post-op complications
Complication
CF (N=397)
ECX (N=376)
n
%
n
%
Any complication
225
57%
234
62%
Respiratory
107
27%
126
34%
Thrombo-embolic
16
4%
17
5%
Infection
57
14%
56
15%
Cardiac
44
11%
45
12%
Surgery related
36
9%
42
11%
Haematological
18
5%
16
4%
Chylothorax
12
3%
15
4%
Anastomotic
44
11%
38
10%
Other
28
7%
28
7%
Required revisional
operation
34
9%
30
8%
Died within 30 days
8
2%
10
2%
Died within 90 days
17
4%
20
5%
Alderson,Cunninghamet al ASCO 2015
TheRoyalMarsden
OE02 update
Trial Design
Resectable carcinoma of the
oesophagus
RANDOMISE
CS
Chemotherapy
and then surgery
S
Surgery alone